Literature DB >> 10902608

Poor correspondence between predicted and experimental binding of peptides to class I MHC molecules.

M H Andersen1, L Tan, I Søndergaard, J Zeuthen, T Elliott, J S Haurum.   

Abstract

Naturally processed peptides presented by class I major histocompatibility complex (MHC) molecules display a characteristic allele specific motif of two or more essential amino acid side chains, the so-called peptide anchor residues, in the context of an 8-10 amino acid long peptide. Knowledge of the peptide binding motif of individual class I MHC molecules permits the selection of potential peptide antigens from proteins of infectious organisms that could induce protective T-cell-mediated immunity. Several methods have been developed for the prediction of potential class I MHC binding peptides. One is based on a simple scanning for the presence of primary peptide anchor residues in the sequence of interest. A more sophisticated technology is the utilization of predictive computer algorithms. Here, we have analyzed the experimental binding of 84 peptides selected on the basis of the presence of peptide binding motifs for individual class I MHC molecules. The actual binding was compared with the results obtained when analyzing the same peptides by two well-known, publicly available computer algorithms. We conclude that there is no strong correlation between actual and predicted binding when using predictive computer algorithms. Furthermore, we found a high number of false-negatives when using a predictive algorithm compared to simple scanning for the presence of primary anchor residues. We conclude that the peptide binding assay remains an important step in the identification of cytotoxic T lymphocyte (CTL) epitopes which can not be substituted by predictive algorithms.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10902608     DOI: 10.1034/j.1399-0039.2000.550603.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  14 in total

Review 1.  Rational design of peptide-based tumor vaccines.

Authors:  Wilson S Meng; Lisa H Butterfield
Journal:  Pharm Res       Date:  2002-07       Impact factor: 4.200

Review 2.  Major histocompatibility complex class I binding predictions as a tool in epitope discovery.

Authors:  Claus Lundegaard; Ole Lund; Søren Buus; Morten Nielsen
Journal:  Immunology       Date:  2010-05-26       Impact factor: 7.397

Review 3.  Advances in the study of HLA-restricted epitope vaccines.

Authors:  Lingxiao Zhao; Min Zhang; Hua Cong
Journal:  Hum Vaccin Immunother       Date:  2013-08-16       Impact factor: 3.452

4.  Prediction of epitopes using neural network based methods.

Authors:  Claus Lundegaard; Ole Lund; Morten Nielsen
Journal:  J Immunol Methods       Date:  2010-10-31       Impact factor: 2.303

5.  Prediction of MHC class I binding peptides by a query learning algorithm based on hidden markov models.

Authors:  Keiko Udaka; Hiroshi Mamitsuka; Yukinobu Nakaseko; Naoki Abe
Journal:  J Biol Phys       Date:  2002-06       Impact factor: 1.365

6.  Cytotoxic T cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide.

Authors:  Katja Mauerer Zirlik; David Zahrieh; Donna Neuberg; John G Gribben
Journal:  Blood       Date:  2006-08-10       Impact factor: 22.113

Review 7.  Mycobacterium tuberculosis-specific CD8+ T cells and their role in immunity.

Authors:  Joshua S M Woodworth; Samuel M Behar
Journal:  Crit Rev Immunol       Date:  2006       Impact factor: 2.214

8.  Discovery of novel targets for multi-epitope vaccines: screening of HIV-1 genomes using association rule mining.

Authors:  Sinu Paul; Helen Piontkivska
Journal:  Retrovirology       Date:  2009-07-06       Impact factor: 4.602

9.  The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase.

Authors:  Rikke Baek Sørensen; Linda Berge-Hansen; Niels Junker; Christina Aaen Hansen; Sine Reker Hadrup; Ton N M Schumacher; Inge Marie Svane; Jürgen C Becker; Per thor Straten; Mads Hald Andersen
Journal:  PLoS One       Date:  2009-09-07       Impact factor: 3.240

Review 10.  T-cell epitope vaccine design by immunoinformatics.

Authors:  Atanas Patronov; Irini Doytchinova
Journal:  Open Biol       Date:  2013-01-08       Impact factor: 6.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.